Novartis AG NVS:NYSE (Depositary Receipt)
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
|---|---|---|---|---|
| 90.76 | 1.03 1.15% | 3.08% | 1,291,618 | 1.6M |
Latest News Headlines for Novartis AG
Editor Note: For more information about this release, please scroll to bottom. LONDON, October 6, 2014 /PRNewswire/ -- Investor-Edge has initiated coverage on the following equities: AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and CTI BioPharma Corporation (NASDAQ: CTIC). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 03, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,009.69, up 1.24% and the NASDAQ Composite closed at 4,475.62, up 1.03%. The S&P; 500 finished the session 1.12% higher at 1,967.90. During the trading session, all the ten sectors finished on a higher note. The S&P; 500 Health Care Sector Index ended the day at 745.09, up 1.97%, with the index advancing 3.29% in the previous three months. Register for your complimentary reports on these five stocks at:
Company Background
Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. It has five segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics, and consumer health, which include over-the-counter medicines (OTC) and Animal Health. In February 2014, it acquired CoStim Pharmaceuticals, Inc.
collapse, right-facing arrow indicating collapsed view of sectionOverview
| Bid | Size | -- | -- |
|---|---|
| Ask | Size | -- | -- |
| Price Open | 88.95 |
| Previous Close | 89.73 |
| Day High | 90.83 |
| Day Low | 88.93 |
| 52 Week High | 9/17/2014 | 95.50 |
| 52 Week Low | 10/10/2013 | 72.77 |
| % Off 52 Week High | (4.96)% |
| % Off 52 Week Low | 24.72% |
| Beta (5 Yr) | 0.53 |
| Volatility Avg | 10/7/2014 | 15.58 |
| 10-Day Avg. Volume | 1,573,429 |
| Market data is delayed by at least 20 minutes. | |
collapse, right-facing arrow indicating collapsed view of sectionFundamentals
| EPS (TTM) | 6/30/2014 | 3.79 |
|---|---|
| P/E Ratio | 6/30/2014 | 23.7 |
| Market Cap | Mega Cap | 222.1B |
| Shares Outstanding | 2.45B |
| Float | 412.8M |
collapse, right-facing arrow indicating collapsed view of sectionDividends
| Dividend Yield | 3.08% |
|---|---|
| Ex-Date | 2/27/2014 |
| Dividend Announcement | 2/3/2014 |
| Date of Record | 3/3/2014 |
| Payable | $2.7598 - ANN |
| Payable Date | 4/10/2014 |
Peers Information HelpNVS Novartis AG vs. Peers
| Peers | |
|---|---|
NVS Novartis AG | 11.63% |
Johnson & Johnson | 11.79% |
Pfizer Inc. | -6.01% |
Merck & Co., Inc. | 16.80% |
Abbott Laboratories | 8.17% |
NVS Novartis AG | 3.04% |
Johnson & Johnson | 2.73% |
Pfizer Inc. | 3.61% |
Merck & Co., Inc. | 3.01% |
Abbott Laboratories | 2.12% |
NVS Novartis AG | 1.15% |
Johnson & Johnson | 2.46% |
Pfizer Inc. | 2.05% |
Merck & Co., Inc. | 2.94% |
Abbott Laboratories | 1.64% |